Comparing anticoagulants for platelet function analysis in hemostasis
Choice of Anticoagulant for Primary Hemostasis Studies With PFA200® (Platelet Function Analyser)
Centre Hospitalier Universitaire Dijon · NCT06753838
This study is testing whether a new type of blood collection tube can give better results for patients with bleeding disorders compared to the standard tube used for checking how well blood clots.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire Dijon (other) |
| Locations | 1 site (Dijon) |
| Trial ID | NCT06753838 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of different anticoagulants in platelet function analysis, specifically comparing conventional citrate tubes with BAPA tubes. The PFA test will be performed on patients receiving hemostasis consultations at a specialized treatment center, where blood samples will be collected using both types of tubes. The goal is to determine if the BAPA tube, which uses a different mechanism to block coagulation, yields more reliable results with less technical difficulty. This could enhance the understanding of primary hemostasis and improve patient care in bleeding disorders.
Who should consider this trial
Good fit: Ideal candidates include adults receiving hemostasis consultations who are undergoing a prescribed PFA test.
Not a fit: Patients who are under legal protection, pregnant, or unable to provide consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate assessments of platelet function, improving diagnosis and treatment for patients with bleeding disorders.
How similar studies have performed: While this approach is relatively novel, previous studies have indicated the importance of anticoagulant choice in platelet function testing, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Person having given their non-opposition * Person of legal age * Person receiving a haemostasis consultation at the haemophilia and haemorrhagic diseases treatment center followed by a blood sample with a PFA test prescribed by the doctor (the test is not added for the study). Exclusion Criteria: * persons under legal protection (curatorship, guardianship) * persons subject to a court protection order * pregnant, parturient or breast-feeding women * adult incapable or unable to give consent * minor
Where this trial is running
Dijon
- CHU Dijon Bourgogne — Dijon, France (RECRUITING)
Study contacts
- Study coordinator: Emmanuel De Maistre
- Email: emmanuel.demaistre@chu-dijon.fr
- Phone: 03 80 29 32 57
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hemostasis